358 related articles for article (PubMed ID: 34372553)
1. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.
Trombetta CM; Marchi S; Viviani S; Manenti A; Benincasa L; Ruello A; Bombardieri E; Vicenti I; Zazzi M; Montomoli E
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372553
[TBL] [Abstract][Full Text] [Related]
2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
3. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
5. Novel SARS-CoV-2 variants: the pandemics within the pandemic.
Boehm E; Kronig I; Neher RA; Eckerle I; Vetter P; Kaiser L;
Clin Microbiol Infect; 2021 Aug; 27(8):1109-1117. PubMed ID: 34015535
[TBL] [Abstract][Full Text] [Related]
6. Fast-spreading COVID variant can elude immune responses.
Callaway E
Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
[No Abstract] [Full Text] [Related]
7. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Focosi D; Maggi F
Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
10. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
[TBL] [Abstract][Full Text] [Related]
11. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
12. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
Front Immunol; 2022; 13():888794. PubMed ID: 35711424
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.
Amanat F; Strohmeier S; Meade PS; Dambrauskas N; Mühlemann B; Smith DJ; Vigdorovich V; Sather DN; Coughlan L; Krammer F
PLoS Biol; 2021 Dec; 19(12):e3001384. PubMed ID: 34914685
[TBL] [Abstract][Full Text] [Related]
16. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
[TBL] [Abstract][Full Text] [Related]
17. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
19. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
20. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
Sulbaran G; Maisonnasse P; Amen A; Effantin G; Guilligay D; Dereuddre-Bosquet N; Burger JA; Poniman M; Grobben M; Buisson M; Dergan Dylon S; Naninck T; Lemaître J; Gros W; Gallouët AS; Marlin R; Bouillier C; Contreras V; Relouzat F; Fenel D; Thepaut M; Bally I; Thielens N; Fieschi F; Schoehn G; van der Werf S; van Gils MJ; Sanders RW; Poignard P; Le Grand R; Weissenhorn W
Cell Rep Med; 2022 Feb; 3(2):100528. PubMed ID: 35233549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
